We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current AGNPF market cap is 2M. The company's latest EPS is CAD -0.0184 and P/E is -3.80.
| Year End August 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -7.56M | -7.44M | -5.13M | -6.29M | -2.41M |
| Net Income | -8.54M | -7.73M | -6.05M | -6.78M | -503k |
| Year End August 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Total Assets | 12.82M | 10.14M | 8.14M | 4.19M | 3.94M |
| Total Liabilities | 607k | 1.02M | 2.52M | 2.72M | 1.78M |
| Total Equity | 12.22M | 9.12M | 5.63M | 1.47M | 2.17M |
| Year End August 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Operating | -6.61M | -7.82M | -2.91M | -2.55M | -2.71M |
| Investing | -100k | -124k | -145k | -60k | 2.28M |
| Financing | 12.62M | 4.25M | 2.06M | 1.33M | 900k |
| Market Cap | 2M |
| Price to Earnings Ratio | -3.80 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 3.21 |
| Price to Book Ratio | 0.88 |
| Dividend Yield | - |
| Shares Outstanding | 27.3M |
| Average Volume (1 week) | 3.52k |
| Average Volume (1 Month) | 34.54k |
| 52 Week Change | 32.93% |
| 52 Week High | 0.123 |
| 52 Week Low | 0.0375 |
| Spread (Intraday) | 0.11 (83.95%) |
| Company Name | Algernon Pharmaceuticals Inc (QB) |
| Address |
suite 1500 - 1055 west georgia street vancouver, british columbia V6E 4N7 |
| Website | https://www.algernonpharmaceuticals.com |
| Industry | surgical,med instr,apparatus (3841) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
